TY - JOUR
T1 - Gelsolin immunoreactivity in corneal amyloid, wound healing, and macular and granular dystrophies
AU - Rodrigues, M. M.
AU - Rajagopalan, S.
AU - Jones, K.
AU - Nirankari, V.
AU - Wisniewski, T.
AU - Frangione, B.
AU - Gorevic, P. D.
N1 - Funding Information:
Accepted for publication Jan. 20, 1993. From the Department of Ophthalmology, University of Maryland at Baltimore, Baltimore, Maryland (Drs. Rodrigues, Rajagopalan, and Nirankari and Mrs. Jones); the Department of Pathology, New York University School of Medicine, New York, New York (Drs. Wisniewski and Frangione); and the Department of Medicine, State University of New York, Health Sciences Center, Stony Brook, New York (Dr. Gorevic). This study was supported in part by a Senior Scientist Investigator Award from Research to Prevent Blindness, Inc.. New York, New York (Dr. Rodrigues). Reprint requests to M. M. Rodrigues, M.D., Dept. of Ophthalmology, University of Maryland at Baltimore, 10 S. Pine St., Baltimore, MD 21201.
PY - 1993
Y1 - 1993
N2 - Immunohistologic studies of tissue sections obtained from patients with type 1 or type 2 lattice corneal dystrophy, polymorphic amyloid degeneration, or gelatinous amyloid degeneration were performed by using a monoclonal antibody raised to a chymotryptic fragment inclusive of the carboxy-terminal half of plasma gelsolin, and also with a series of polyclonal antibodies specific for synthetic peptides corresponding to immunogenic epitopes of gelsolin. These epitopes are parts of sequences at the amino- and carboxy- terminal ends of gelsolin, as well as adjacent to and inclusive of the codon 187 mutant 7-11 kD fragment that has been shown to be the subunit protein of amyloid fibrils occurring systemically in patients affected by Finnish type familial amyloidosis. These antibodies were also tested on tissue sections obtained from patients with granular and macular corneal dystrophy, corneal wounds, and normal control corneas. Specificity of staining was established by absorption with gelsolin purified from plasma, or the appropriate synthetic peptide. Gelsolin immunoreactivity was detected in the conjunctival and skin amyloid in familial amyloidosis by using familial amyloid (Finnish type) antibody. In other types of corneal amyloid, including lattice dystrophy type 1, immunoreactivity with gelsolin and synthetic peptides was observed adjacent to the deposits, but rarely within them. In macular dystrophy, variable staining of the deposits could result from the association of subunit proteins with glycosaminoglycans.
AB - Immunohistologic studies of tissue sections obtained from patients with type 1 or type 2 lattice corneal dystrophy, polymorphic amyloid degeneration, or gelatinous amyloid degeneration were performed by using a monoclonal antibody raised to a chymotryptic fragment inclusive of the carboxy-terminal half of plasma gelsolin, and also with a series of polyclonal antibodies specific for synthetic peptides corresponding to immunogenic epitopes of gelsolin. These epitopes are parts of sequences at the amino- and carboxy- terminal ends of gelsolin, as well as adjacent to and inclusive of the codon 187 mutant 7-11 kD fragment that has been shown to be the subunit protein of amyloid fibrils occurring systemically in patients affected by Finnish type familial amyloidosis. These antibodies were also tested on tissue sections obtained from patients with granular and macular corneal dystrophy, corneal wounds, and normal control corneas. Specificity of staining was established by absorption with gelsolin purified from plasma, or the appropriate synthetic peptide. Gelsolin immunoreactivity was detected in the conjunctival and skin amyloid in familial amyloidosis by using familial amyloid (Finnish type) antibody. In other types of corneal amyloid, including lattice dystrophy type 1, immunoreactivity with gelsolin and synthetic peptides was observed adjacent to the deposits, but rarely within them. In macular dystrophy, variable staining of the deposits could result from the association of subunit proteins with glycosaminoglycans.
UR - http://www.scopus.com/inward/record.url?scp=0027316199&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)71464-3
DO - 10.1016/S0002-9394(14)71464-3
M3 - Article
C2 - 7683843
AN - SCOPUS:0027316199
SN - 0002-9394
VL - 115
SP - 644
EP - 652
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -